An update on respiratory syncytial virus antiviral agents

Expert Opinion on Investigational Drugs

Volumn 10, Issue 2, 2001, Pages 297-308

  Prince, G A ^a  

^a Virion Systems Inc   (United States)

Author keywords

Anti inflammatory; Antiviral; Respiratory syncytial virus; RSV; Therapy

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; BARLERIA PRIONITIS EXTRACT; BENZANTHRONE; CL 387626; FELVIZUMAB; HEPARIN; HNK 20; IMMUNOGLOBULIN; IRIDOID; LIPID; LITHRAEA MOLLEOIDES EXTRACT; METAL DERIVATIVE; MONOCLONAL ANTIBODY; NMSO 3; NUCLEOSIDE ANALOG; PALIVIZUMAB; PLACEBO; PLANT EXTRACT; POLYGONUM PUNCTATUM EXTRACT; POLYOXOMETALATE; PROTEIN INHIBITOR; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE; RHSZ 19; RIBAVIRIN; ROZITES CAPERATA EXTRACT; SIALIC ACID DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERBACOSIDE;

ADULT; AEROSOL; ANIMAL MODEL; ARTICLE; CELL CULTURE; CHILD; DEVELOPING COUNTRY; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; ECONOMIC ASPECT; GOVERNMENT; HIGH RISK POPULATION; HOST; HUMAN; INCIDENCE; INDUSTRY; INFANT; INFLAMMATION; LABORATORY; LOWER RESPIRATORY TRACT INFECTION; MEDIATOR; MEDICAL RESEARCH; MOUSE; NONHUMAN; PATHOGENESIS; PLANT; POLYGONUM PUNCTATUM; REINFECTION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; ROZITES CAPERATA; SCREENING; VACCINATION; VIRUS LOAD;

ANTIVIRAL AGENTS; OLIGONUCLEOTIDES, ANTISENSE; RESPIRATORY SYNCYTIAL VIRUSES; RNA, VIRAL;

EID: 0035147049     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.2.297     Document Type: Article

References (78)

1. Perspectives for the chemotherapy of respiratory syncytial virus (RSV) infections
2. Respiratory syncytial virus (RSV) disease and prospects for its control
3. Chemotherapy of respiratory viruses: Prospects and challenges
4. Respiratory syncytial virus antiviral agents
5. Recent progress in antiviral chemotherapy for respiratory syncytial virus infections
6. Novel anti-RSV dianionic dendrimer-like compounds: Design, synthesis and biological evaluation
7. Respiratory syncytial virus: Recent progress towards the discovery of effective prophylactic and therapeutic agents
8. Respiratory syncytial virus
9. Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: Clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant
10. The fusion glycoprotein of human respiratory syncytial virus facilitates virus attachment and infectivity via an interaction with cellular heparan sulfate
11. Histologic profiles of primary respiratory syncytial virus (RSV) infection, reinfection and vaccine-enhanced RSV disease in the cotton rat (Sigmodon bispidus)
12. Heparin-like structures on respiratory syncytial virus are involved in its infectivity in vitro
13. Identification of a linear heparin binding domain for human respiratory syncytial virus attachment glycoprotein G
14. Enhanced neutralization of human respiratory syncytial virus by mixtures of monoclonal antibodies to the attachment (G) glycoprotein
15. Identification of multiple protective epitopes (protectopes) in the central conserved domain of a prototype human respiratory syncytial virus G protein
16. A RhoA-derived peptide inhibits syncytium formation induced by respiratory syncytial virus and parainfluenza virus Type 3
17. Novel and specific respiratory syncytial virus inhibitors that target virus fusion
18. CL387626 exhibits marked and unusual antiviral activity against respiratory syncytial virus in tissue culture and in cotton rats
19. Inhibition of respiratory syncytial virus by a new class of chemotherapeutic agents
20. Antiviral activity of NMSO3 against respiratory syncytial virus infection in vitro and in vivo
21. A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZ19
22. Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections
23. Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in healthy children
24. Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation-a compassionate use experience
25. Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: A consensus opinion
26. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein
27. A humanized monoclonal antibody against respiratory syncytial virus (palivizumab) inhibits RSV-induced neurogenic-mediated inflammation in rat airways
28. Treatment of respiratory syncytial virus bronchiolitis and pneumonia in a cotton rat model using systemically administered monoclonal antibody (palivizumab) and glucocorticosteroid
29. Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209863) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease
30. Intranasal antibody prophylaxis for protection against viral disease
31. Effects of humanization by variable domain resurfacing on the antiviral activity of a single-chain antibody against respiratory syncytial virus
32. Prophylactic administration of a complementarity-determining region derived from a neutralizing monoclonal antibody is effective against respiratory syncytial virus infection in BALB/c mice
33. Two neutralizing human anti-RSV antibodies: Cloning, expression and characterization
34. Isolation of a second recombinant human respiratory syncytial virus monoclonal antibody fragment (Fab RSVF2-5) that exhibits therapeutic efficacy in vivo
35. Monoclonal antibody-resistant mutants selected with a respiratory syncytial virus-neutralizing human antibody Fab fragment (Fab 19) define a unique epitope on the fusion (F) glycoprotein
36. Respiratory syncytial virus infections and ribavirin treatment. Clinical and economic evaluation
37. Ribavirin in ventilated respiratory syncytial virus bronchiolitis
38. Reduced long-term respiratory morbidity after treatment of respiratory syncytial virus bronchiolitis with ribavirin in previously healthy infants: A preliminary report
39. Prospective follow-up and pulmonary functions from a placebo-controlled randomized trial of ribavirin therapy in respiratory syncytial virus bronchiolitis
40. The outcome of 26 patients with respiratory syncytial virus infection following allogeneic stem cell transplantation
41. Outbreak of respiratory syncytial virus infection in adult bone marrow transplant unit: Role of ribavirin treatment and recommendations for prevention of RSV infection in high risk patients
42. Respiratory syncytial virus infection in adult BMT recipients: Effective therapy with short duration nebulised ribavirin
43. Pre-emptive use of aerosolized ribavirin in the treatment of asymptomatic pediatric marrow transplant patients testing positive for RSV
44. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: Combination therapy with aerosolized ribavirin and intravenous immunoglobulin
45. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: A comparison with ribavirin and demonstration of antiviral additivity with alpha interferon
46. Potent inhibition of respiratory syncytial virus replication using a 2-5A-antisense chimera targeted to signals within the virus genomic RNA
47. 2-5A-DNA conjugate inhibition of respiratory syncytial virus replication: Effects of oligonucleotide structure modifications and RNA target site selection
48. Isolation and partial characterization of an antiviral, RC-183, from the edible mushroom Rozites caperate
49. New iridoids from the medicinal plant Barleria prionitis with potent activity against respiratory syncytial virus
50. Antiviral activity in Argentine medicinal plants
51. Evolution of antiviral activity in the ribonuclease A gene superfamily: Evidence for a specific interaction between eosinophil-derived neurotoxin (EDN/RNase 2) and respiratory syncytial virus
52. Recombinant human eosinophil-derived neurotoxin/RNAse 2 functions as an effective antiviral agent against respiratory syncytial virus
53. Novel anti-respiratory syncytial (RS) viral compounds: Benzodithiin derivatives
54. Efficacy of RD3-0028 aerosol treatment against respiratory syncytial virus infection in immunosuppressed mice
55. 2-type cytokine expression by activated T lymphocytes from the lung and spleen during the inflammatory response to respiratory syncytial virus
56. Role of interferon gamma in the pathogenesis of primary respiratory syncytial virus infection in BALB/c mice
57. Novel pathways in the pathogenesis of respiratory syncytial virus disease
58. Chemokines, cytokines and inflammatory cells in respiratory syncytial virus infection: Similarities to allergic responses
59. Increased number of T cells committed to IL-5 production after respiratory syncytial virus (RSV) infection of human mononuclear cells in vitro
60. Severity of respiratory syncytial virus disease related to type and genotype of virus and to cytokine values in nasopharyngeal secretions
61. Activator protein-1 is the preferred transcription factor for cooperative interaction with nuclear factor-κB in respiratory syncytial virus-induced interleukin-8 gene expression in airway epithelium
62. Respiratory syncytial virus-induced chemokine expression in the lower airways. Eosinophil recruitment and degranulation
63. Airway epithelial cell-induced activation of monocytes and eosinophils in respiratory syncytial viral infection
64. Respiratory syncytial virus upregulates expression of the substance P receptor in rat lungs
65. The interaction of neutrophils with respiratory epithelial cells in viral infection
66. T-cell subsets and lung inflammation: Lessons from respiratory syncytial virus
67. Enzyme-linked immunosorbent assay to assess respiratory syncytial virus concentration and correlate results with inflammatory mediators in tracheal secretions
68. Prednisolone treatment of respiratory syncytial virus infection: A randomized controlled trial of 147 infants
69. No objective benefit from steroids inhaled via a spacer in infants recovering from bronchiolitis
70. Randomised placebo controlled trial of nebulised corticosteroids in acute respiratory syncytial viral bronchiolitis
71. Prednisolone plus albuterol versus albuterol alone in mild to moderate bronchiolitis
72. Systemic corticosteroids in infant bronchiolitis: A meta-analysis
73. Therapy for respiratory tract infections caused by respiratory syncytial virus
74. Inhaled corticosteroids during and after respiratory syncytial virus-bronchiolitis may decrease subsequent asthma
75. A randomized, double-blind, placebo-controlled trial of dexamethasone in severe respiratory syncytial virus infection: Effects on viral load and clinical outcomes
76. Transcriptional induction of multiple cytokines by human respiratory syncytial virus requires activation of NF-κB and is inhibited by sodium salicylate and aspirin
77. Respiratory syncytial virus infection and G and/or SH protein expression contribute to substance P, which mediates inflammation and enhanced pulmonary disease in BALB/c mice
78. A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia